### Serbia

**Population 2018**: 8.8 million

#### Tuberculosis profile

<table>
<thead>
<tr>
<th>Estimates of TB burden, 2018</th>
<th>Number (thousands)</th>
<th>Rate (per 100,000 population)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total TB incidence</td>
<td>1.5 (1.3–1.8)</td>
<td>17 (15–20)</td>
</tr>
<tr>
<td>HIV-positive TB incidence</td>
<td>&lt;0.01 (&lt;0.01–&lt;0.01)</td>
<td>0.06 (0.03–0.09)</td>
</tr>
<tr>
<td>MDR-RR-TB incidence</td>
<td>0.022 (0.01–0.039)</td>
<td>0.25 (0.11–0.45)</td>
</tr>
<tr>
<td>HIV-negative TB incidence</td>
<td>0.055 (0.05–0.061)</td>
<td>0.63 (0.57–0.69)</td>
</tr>
<tr>
<td>HIV-positive TB mortality</td>
<td>0 (0–&lt;0.01)</td>
<td>0.01 (0–0.02)</td>
</tr>
</tbody>
</table>

#### Estimated proportion of TB cases with MDR/RR-TB, 2018

- New cases: 1.1%
- Previously treated cases: 4.7% (1.3–11)

#### TB case notifications, 2018

- Total new and relapse: 1,330

#### Universal health coverage and social protection

- TB treatment coverage (notified/estimated incidence), 2018: 87% (75–100)
- TB patients facing catastrophic total costs

#### TB/HIV care in new and relapse TB patients, 2018

- Patients with known HIV status who are HIV-positive: 8 (14%)
  - on antiretroviral therapy: 8 (100%)

#### Drug-resistant TB care, 2018

- % of bacteriologically confirmed TB cases tested for rifampicin resistance: 56%
  - New cases: 56%
  - Previously treated cases: 40%

#### Treatment success rate and cohort size

- New and relapse cases registered in 2017: 86% 1,440
- Previously treated cases, excluding relapse, registered in 2017: 56% 18
- HIV-positive TB cases registered in 2017: 75% 8
- MDR-RR-TB cases started on second-line treatment in 2016: 70% 10
- XDR-TB cases started on second-line treatment in 2016: 0% 1

#### TB preventive treatment, 2018

- % of HIV-positive people (newly enrolled in care) on preventive treatment
- % of children (aged <5) household contacts of bacteriologically-confirmed TB cases on preventive treatment

#### TB financing, 2019

- National TB budget (US$ millions): 8.2
  - Funding source: 96% domestic, 0% international, 1% unfunded

---

**Footnotes**

- Ranges represent uncertainty intervals
- MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
- Calculated for pulmonary cases only
- Includes cases with unknown previous TB treatment history
- Includes patients diagnosed before 2018 and patients who were not laboratory-confirmed